This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Find Cheap Highly-Ranked Stocks Trading Under $10 for 2020
by Benjamin Rains
Here are 5 of the 36 highly-ranked stocks trading under $10 a share that made it through today's screen...
Are Options Traders Betting on a Big Move in Paratek Pharmaceuticals (PRTK) Stock?
by Zacks Equity Research
Investors need to pay close attention to Paratek Pharmaceuticals (PRTK) stock based on the movements in the options market lately.
Paratek Pharmaceuticals (PRTK) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Paratek (PRTK) delivered earnings and revenue surprises of 5.66% and 8.43%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Paratek Pharmaceuticals (PRTK) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Paratek (PRTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Paratek Pharmaceuticals (PRTK) Q3 Earnings Expected to Decline
by Zacks Equity Research
Paratek (PRTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Paratek Pharmaceuticals (PRTK) Catches Eye: Stock Jumps 10.2%
by Zacks Equity Research
Paratek Pharmaceuticals (PRTK) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.
Paratek Pharmaceuticals (PRTK) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Paratek (PRTK) delivered earnings and revenue surprises of 12.07% and 9.95%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Paratek Pharmaceuticals (PRTK) Q2 Earnings Expected to Decline
by Zacks Equity Research
Paratek (PRTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Melinta (MLNT) Announces Preliminary Product Sales for Q2
by Zacks Equity Research
Melinta (MLNT) announces preliminary sales for the second quarter. However, sales number suggests estimates miss for the quarter. Shares fall.
Paratek Pharmaceuticals (PRTK) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Paratek (PRTK) delivered earnings and revenue surprises of 8.33% and 79.55%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Paratek Pharmaceuticals (PRTK) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Paratek (PRTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Paratek Pharmaceuticals (PRTK) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Paratek (PRTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Paratek Pharmaceuticals (PRTK) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Paratek (PRTK) delivered earnings and revenue surprises of -18.82% and -99.15%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Paratek Pharmaceuticals (PRTK) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Paratek (PRTK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Paratek Pharmaceuticals (PRTK) in Focus: Stock Moves 8.7% Higher
by Zacks Equity Research
Paratek Pharmaceuticals (PRTK) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Paratek (PRTK) Gets FDA Approval for Nuzyra and Seysara
by Zacks Equity Research
Paratek (PRTK) gets FDA approval for Nuzyra for the treatment of serious community-acquired bacterial infections and Seysara for the treatment of acne.
Implied Volatility Surging for Paratek Pharmaceuticals (PRTK) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Paratek Pharmaceuticals (PRTK) stock based on the movements in the options market lately.
Foamix's Acne Candidate Succeeds in Study, Shares Rally
by Zacks Equity Research
Foamix's (FOMX) acne candidate, FMX101, meets co-primary endpoints in the third phase III study, FX2017-22.
Paratek Pharmaceuticals (PRTK) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Paratek (PRTK) delivered earnings and revenue surprises of -1.08% and -60.00%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Paratek's Antibiotic Candidate Gets FDA Committee Date
by Zacks Equity Research
Paratek's (PRTK) NDA for its antibiotic candidate, omadacycline, to be reviewed by an FDA advisory committee on Aug 8.
What's in Store for Endocyte (ECYT) This Earnings Season?
by Zacks Equity Research
Endocyte (ECYT) is expected to provide updates on pipeline candidates when it reports first-quarter 2018 results on May 9 after the market closes.
5 Biotech Stocks Set to Beat Estimates This Earnings Season
by Zacks Equity Research
Given the large number of biotech firms, the task of selecting stocks with possibilities to beat estimates could appear daunting. We pick five biotech stocks likely to deliver an earnings surprise.
BioDelivery Sciences (BDSI) Q1 Earnings: What to Expect?
by Zacks Equity Research
Investor focus will be on the performance of BioDelivery Sciences' (BDSI) two marketed drugs, Belbuca (chronic pain) and Bunavail (opioid-dependence).
Paratek's (PRTK) NDAs for Omadacycline Get Priority Review
by Zacks Equity Research
Paratek Pharmaceuticals (PRTK) is seeking approval for its antibiotic candidate, omadacycline, for the treatment of CABP and ABSSSI in the United States.
The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Bio-Techne, Exelixis, Paratek and Bioverativ
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Bio-Techne, Exelixis, Paratek and Bioverativ